drugset / Trial / NCT00087516

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

NCT00087516

Phase 3 Completed 741 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

Timeline

Start
2004-06
Primary completion
2005-07
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sitagliptin Small molecule 100 mg Oral
Comparator Sitagliptin Small molecule 200 mg Oral
Comparator Metformin Small molecule 500 mg Oral
Comparator Metformin Small molecule 850 mg Oral
Comparator Metformin Small molecule 1000 mg Oral